After 7 days, anti-TGFβ treatment was associated with a significant increase in tumor-infiltrating CD45+ immune cells, mainly due to CD8+ T cells and DCs (i.e., CD11b), and a significant reduction of TAM2 (Fig. 3A-C). The gene discussed is PTPRC; the disease is neoplasm.